-$0.57 EPS Expected for Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) This Quarter

Wall Street brokerages expect that Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) will post earnings of ($0.57) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Kiniksa Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.60) and the highest is ($0.54). Kiniksa Pharmaceuticals reported earnings per share of ($0.88) in the same quarter last year, which would suggest a positive year-over-year growth rate of 35.2%. The company is scheduled to issue its next quarterly earnings results on Thursday, March 5th.

According to Zacks, analysts expect that Kiniksa Pharmaceuticals will report full-year earnings of ($2.99) per share for the current fiscal year, with EPS estimates ranging from ($3.02) to ($2.96). For the next financial year, analysts anticipate that the company will report earnings of ($2.63) per share, with EPS estimates ranging from ($2.76) to ($2.50). Zacks’ EPS calculations are an average based on a survey of research firms that cover Kiniksa Pharmaceuticals.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its quarterly earnings results on Monday, October 28th. The company reported ($0.49) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.72) by $0.23.

Several equities analysts have recently weighed in on the company. Goldman Sachs Group upgraded Kiniksa Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their price target for the company from $16.00 to $18.00 in a research report on Friday, December 6th. ValuEngine cut Kiniksa Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, January 15th. Finally, Zacks Investment Research upgraded Kiniksa Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Kiniksa Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $21.75.

Several hedge funds and other institutional investors have recently made changes to their positions in KNSA. JPMorgan Chase & Co. grew its position in shares of Kiniksa Pharmaceuticals by 33.1% in the second quarter. JPMorgan Chase & Co. now owns 3,832 shares of the company’s stock valued at $52,000 after purchasing an additional 952 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in Kiniksa Pharmaceuticals by 50.1% during the second quarter. Charles Schwab Investment Management Inc. now owns 36,013 shares of the company’s stock worth $488,000 after buying an additional 12,021 shares in the last quarter. Bank of New York Mellon Corp grew its position in Kiniksa Pharmaceuticals by 20.1% during the second quarter. Bank of New York Mellon Corp now owns 56,371 shares of the company’s stock worth $764,000 after buying an additional 9,427 shares in the last quarter. Northern Trust Corp grew its position in Kiniksa Pharmaceuticals by 17.1% during the second quarter. Northern Trust Corp now owns 154,899 shares of the company’s stock worth $2,097,000 after buying an additional 22,645 shares in the last quarter. Finally, Parametric Portfolio Associates LLC grew its position in Kiniksa Pharmaceuticals by 17.9% during the second quarter. Parametric Portfolio Associates LLC now owns 31,595 shares of the company’s stock worth $428,000 after buying an additional 4,787 shares in the last quarter. Institutional investors own 29.85% of the company’s stock.

Shares of NASDAQ KNSA traded down $0.36 during mid-day trading on Friday, hitting $14.93. The company had a trading volume of 345,600 shares, compared to its average volume of 320,956. The company has a market capitalization of $839.09 million, a price-to-earnings ratio of -4.40 and a beta of -0.95. Kiniksa Pharmaceuticals has a 1 year low of $5.01 and a 1 year high of $23.04. The stock’s 50-day moving average price is $12.96 and its 200-day moving average price is $10.29.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis.

See Also: Roth IRA

Get a free copy of the Zacks research report on Kiniksa Pharmaceuticals (KNSA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kiniksa Pharmaceuticals (NASDAQ:KNSA)

Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.